Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
Kristin Kaasen JørgensenGuro L GollJoe SextonNils BolstadInge C OlsenØivind AsakIngrid P BersetIngrid M BlomgrenKatrine DvergsnesJon FlorholmenSvein O FrigstadMagne HenriksenJon HagforsGert Huppertz-HaussEspen A HaavardsholmRolf A KlaasenBjørn MoumGeir NorabergUlf PrestegårdJan H RydningLiv SagatunKathrine A SeebergRoald TorpCecilia VoldDavid J WarrenCarl M YstrømKnut E A LundinTore KvienProf Jørgen JahnsenPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
ClinicalTrials.gov, number NCT02148640.